Donepezil was discovered to be one of the most effective to help people living with Dementia improve their cognition, in a new study. This study ranked the effectiveness of the drugs as well as their safety as the two main criteria to earn their ranks. Four drugs in total were tested and given to participants to increase their rates of concentration, memory, alertness and moods. Although donepezil was seen to be the most effective in this study published in the journal of the American Geriatrics Society, the drug caused those who took it to experience more negative side effects than people who took the placebo. Some of these side effects included diarrhea, and nausea that led to vomiting. It was found in a 2016 Ontario Drug Policy Research report that 146, 593 people in Ontario, 65 years of age and older, used drugs to improve their cognition. So, the goal of this study was to start with a comparative approach to see which one of these drugs were found to be the most useful and least harmful. They compared the four drugs donepezil, rivastigmine, galantamine or memantine in clinical trials that tested the participant’s cognition, function behaviour, global status, and the likelihood of mortality, serious adverse events, falls, bradycardia, headache, diarrhea, vomiting and nausea. Donepezil was the only drug to have outcomes that were observed clinically and statistically, granting it the number one spot on the list.
AUTHOR(S): St. Michael's Hospital
DATE RETRIEVED: October 5th, 2017